Most patients notice a decrease in appetite and fewer cravings within a few weeks
Combine it with other IV therapies, like hydration or B-complex vitamins, for a fully customized experience
The following primary antibodies were used: anti-MC5-R (Alomone Labs, Jerusalem, Israel, # AMR-025), anti--MSH (Bioss, MA, USA, # BS-1848R), anti-phospho-JNK (Cell Signaling Tech, # 4668), anti-JNK (R&D Systems, # AF-1387), anti-phospho-ERK1/2 (Cell Signaling Tech, # 9107), anti-ERK1/2 (Cell Signaling Tech, # 9106), anti-phospho-p38 (Cell Signaling Tech, # 9215), anti-p38 (Cell Signaling Tech, # 9212), anti-phospho-AMPK (Cell Signaling Tech, # 2535), anti-AMPK (Cell Signaling Tech, # 2532), anti-phospho-Akt (R&D Systems, # AF887), anti-Akt (R&D Systems, # MAB2055), anti-phospho-CREB (ThermoFisher, # MA5-11192), anti-CREB (Cell Signaling Tech, #9197) and anti-NT-proBNP (Abcam, # ab13115) antibody
Recently, new therapies like Keytruda have radically changed the treatment of cancer, while more established therapies, like GLP-1s and SGLT2 inhibitors, have suddenly changed the treatment of diabetes and heart failure, respectively
